Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 2/20 | 0.49 |
| ▸ | LTA4H | P09960 | 4/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348339 | 0.92 | CRBN (0.44) | TNFLTA4HCRBNDRD2ESR1 | |
| SCHEMBL29348353 | 0.88 | TNF (0.41) | TNFCRBNHRH3DRD2ESR1 | |
| SCHEMBL29348350 | 0.86 | CRBN (0.49) | CRBNDRD2DDB1 | |
| SCHEMBL29348358 | 0.84 | CRBN (0.50) | CRBNDRD2DDB1 | |
| SCHEMBL29348367 | 0.83 | CRBN (0.47) | CRBNDRD2ESR1ESR2DDB1 | |
| SCHEMBL29348398 | 0.81 | CRBN (0.41) | TNFCRBNDRD2DDB1 | |
| SCHEMBL31068093 | 0.81 | BRD4 (0.45) | CRBNDDB1 | |
| SCHEMBL31068149 | 0.81 | CRBN (0.46) | CRBNDDB1 | |
| SCHEMBL31068109 | 0.81 | CRBN (0.46) | CRBNDDB1 | |
| SCHEMBL29348439 | 0.81 | CRBN (0.46) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |